Back to top

Buy Rating Affirmed on Affimed: Promising Clinical Outlook and Robust Financial Position

Wells Fargo analyst Yanan Zhu maintained a Buy rating on Affimed (AFMD – Research Report) on March 28 and set a price target of $25.00. Yanan Zhu’s...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Affimed N.V. (AFMD)